Last Updated : July 24, 2024
Details
Generic Name:
Rivaroxaban (granules for oral suspension)
Project Status:
Not filed
Therapeutic Area:
Venous Thromboembolic Events
Manufacturer:
Bayer Inc
Brand Name:
Xarelto
Project Line:
Reimbursement Review
Project Number:
NS0022-000
Biosimilar:
No
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
The treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : July 24, 2024